Date: 2011-01-04
Type of information: R&D agreement
Compound: RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.
Company: Santaris Pharma (Denmark) Pfizer (USA - NY)
Therapeutic area:
Type agreement: R&D
Commercialisation
Action mechanism:
Disease:
Details: Santaris Pharma and Pfizer have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.The newly expanded alliance builds on the original collaboration formed in January 2009 between Santaris Pharma A/S and Wyeth, which was acquired by Pfizer Inc. Under the terms of the original collaboration, Santaris Pharma A/S received an upfront payment of $7 million in cash and Wyeth made a $10 million equity investment in Santaris Pharma A/S. Santaris Pharma A/S continues to be eligible to receive milestones and royalties under the original alliance. Pfizer has advanced several programs under the original collaboration and reached a number of early milestones since the inception of the collaboration.
Financial terms: Under the terms of the expanded agreement, Pfizer will make a payment of $14 million for access to Santaris Pharma A/S LNA technology for the development of RNA-targeted drugs. Santaris Pharma A/S is eligible to receive milestone payments of up to $600 million as well as royalties on sales of products that may be developed for up to 10 new RNA targets selected by Pfizer.
Latest news:
